Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.63 |
| ▸ | PPARA | Q07869 | 16/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28745487 | 1.00 | PPARG (0.63) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL1565681 | 0.90 | PPARA (0.57) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL8864038 | 0.88 | CTRC (0.57) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL8935658 | 0.86 | PPARG (0.64) | PPARGPPARASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL8935654 | 0.86 | PPARG (0.64) | PPARGPPARASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13923928 | 0.85 | PPARG (0.65) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL4257140 | 0.85 | PPARG (0.65) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL5508320 | 0.84 | PPARG (0.73) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL8935946 | 0.84 | PPARG (0.73) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL4851925 | 0.83 | PPARG (0.63) | PPARGPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | PPARG 59/4885PPARA 376/4885SMN1; SMN2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.